canada clinical guidance

Psoriasis (assessment & management)

A Canadian clinical summary of psoriasis (assessment & management), with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Canadian guidelines for the management of plaque psoriasis. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:Canadian psoriasis guideline

Source-attributed clinical priorities

  • Assess body and high-impact sites, symptoms, quality of life, joint disease and cardiometabolic comorbidity.
  • Use topical therapy for limited disease and phototherapy or systemic options for more extensive or high-impact disease.
  • Refer suspected psoriatic arthritis, erythroderma, pustular disease or treatment-refractory psoriasis promptly.
  • Ask about joint pain, morning stiffness, dactylitis and enthesitis at every severity level.
sources for this section:Canadian psoriasis guideline

Practical assessment and management workflow

1
Assess body surface and high-impact sites, itch, pain, nails, quality of life and prior treatment.
2
Screen cardiometabolic risk, mood, inflammatory bowel disease and medication triggers.
3
Use topical treatment matched to site and arrange phototherapy or systemic care for extensive or high-impact disease.
4
Monitor response and treatment-specific laboratory, infection and reproductive safety.
sources for this section:Canadian psoriasis guideline

Safety, red flags and urgent escalation

  • Erythroderma, generalized pustular disease or systemic illness needs urgent specialist assessment.
  • A hot swollen joint or rapidly progressive inflammatory arthritis warrants expedited evaluation.
  • Avoid abrupt withdrawal of systemic corticosteroids used for another reason without a coordinated plan.
sources for this section:Canadian psoriasis guideline

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:Canadian psoriasis guideline

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Canadian psoriasis guideline

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Canadian Psoriasis Guidelines CommitteeCanadian guidelines for the management of plaque psoriasisaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.